Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Heart Attacks, Cancer and strokes. Preventative approaches -- Ignore unavailable to you. Want to Upgrade?

To: ig who wrote (38646)	2/1/2024 7:14:40 AM
From: ig	1 Recommendation Recommended By Stan Respond to of 39322

P.S. on the new floater study. I skimmed over it and it looks worth digging into. The technical language in kind of dense, so it could take a while before I have anything else to say about it. ncbi.nlm.nih.gov

To: ig who wrote (38646)	2/1/2024 7:54:30 AM
From: Stan	Respond to of 39322

I'll keep up the dosages for as long as the bottle lasts. If I think it's helping I'll try another. In fact, your article appears to my layman's understanding to provide some hope. 3.1. Human Study In experiment 1, with 160 subjects with SVOs [symptomatic vitreous opacities], we compared the results of MFEs [mixed fruit enzymes] in treating SVOs after three months. The rates of disappearance in SVOs were 55%, 62.5%, and 70% in the 1-, 2-, and 3- capsule groups after three months (p < 0.05), respectively ( Table 1). Therefore, we demonstrated that SVOs should be broken down and absorbed by MFEs. Moreover, the outcomes showed a dose-dependent manner. In other words, the higher amounts of fruit enzyme in the capsules, the stronger the hydrolytic and proteolytic ability for dissolving SVOs. If the patients took at least one capsule of MFEs, SVOs might significantly disappear. Further, the subjects in the placebo were given vitamin C for three months; however, SVOs apparently persisted (p > 0.05).